Catalysts ahead for the smaller players
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
Madrigal changes the tune in Nash
A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.
Madrigal’s Maestro result puts the focus on Nash
Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
EASL 2019 – Novo buys into Gilead’s Nash combo plan
Today’s deal will see the companies take a triple combination into clinical trials.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
EASL 2019 – Viking to push the limits of its Nash contender
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
